February 9, 2017 / 2:44 PM / a year ago

BRIEF-Regeneron says price increases unrelated from innovation will be pushed back on

Feb 9 (Reuters) - Regeneron Pharmaceuticals Inc -

* Regeneron CEO: “As we further diversify our product related revenue stream, we do not plan to provide eylea guidance after 2017”

* Regeneron CEO says Amgen’s asserted patent claims on repatha are invalid and we look forward to pursuing our appeal over the coming months: conf call

* Regeneron’s Bob Terifay says Eylea will continue for co over the years to come

* Regeneron: Eylea sales growth has slowed reflecting normal market dynamics for the product that has been around for over 5 yrs with no price hike since launch

* Regeneron CEO says changes in pharmaceutical drug pricing will need congressional action

* Regeneron CEO “Price increases that are unrelated or uncoupled from innovation will be pushed back on”

* Regeneron CEO: Constant price increases & magnitude of them are reflection of tone deafness on those taking hikes & complexities about how rebates work

* Regeneron CEO: “There is an opportunity to come up with more responsible pricing”, in relation to rheumatoid arthritis drug, sarilumab

* Regeneron CEO: “Pharma is running around saying the middleman (PBM) is taking too much; the middleman says prices are too high and patients are wondering what is really going on”

* Regeneron CEO: “price increases are nice but if you cannot get them you better be able to innovate and that is our sweet spot” Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below